Page last updated: 2024-10-27

fluoxetine and Altidudinal Hemianopia

fluoxetine has been researched along with Altidudinal Hemianopia in 1 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Research Excerpts

ExcerptRelevanceReference
"We randomized 17 consecutive adults 1:1 to 90 days of fluoxetine 20 mg daily vs placebo within 10 days of an ischemic stroke causing isolated homonymous hemianopia."9.69FLUORESCE: A Pilot Randomized Clinical Trial of Fluoxetine for Vision Recovery After Acute Ischemic Stroke. ( Busza, A; Mahon, BZ; Prentiss, EK; Sahin, B; Schneider, CL; Williams, ZR, 2023)
"We randomized 17 consecutive adults 1:1 to 90 days of fluoxetine 20 mg daily vs placebo within 10 days of an ischemic stroke causing isolated homonymous hemianopia."5.69FLUORESCE: A Pilot Randomized Clinical Trial of Fluoxetine for Vision Recovery After Acute Ischemic Stroke. ( Busza, A; Mahon, BZ; Prentiss, EK; Sahin, B; Schneider, CL; Williams, ZR, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Schneider, CL1
Prentiss, EK1
Busza, A1
Williams, ZR1
Mahon, BZ1
Sahin, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fluoxetine for Visual Recovery After Ischemic Stroke[NCT02737930]Phase 217 participants (Actual)Interventional2016-05-31Terminated (stopped due to Slow recruitment and lack of funding to expand to other sites.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Percent Change in Field Points Tested

Visual field recovery is defined as an improvement of more than 6 decibels (dB) in the threshold required to elicit a response at each point in the Humphrey visual field. This is based on the unidirectional test-retest variability of less than 3 dB reported in the Humphrey Field Analyzer manual. The endpoint will be an improvement in threshold values at test locations spanning more than 10 degrees horizontally or 15 degrees vertically in the Humphrey visual field in both eyes at 6 months, based on the definition of visual improvement used by Zhang et al. in their natural history study of stroke patients with hemianopia. (NCT02737930)
Timeframe: 6 months

Interventionpercent of visual field points tested (Mean)
Fluoxetine72.4
Placebo32.1

Mean Percent Change in Post-stroke Retinal Nerve Fiber Layer Thickness

This will be measured by spectral domain optical coherence tomography. Optical coherence tomography is a method of using low-coherence interferometry to determine the echo time delay and magnitude of backscattered light reflected off an object of interest. This method can be used to scan through the layers of a structured tissue sample such as the retina with very high axial resolution (3 to 15 μm), providing images demonstrating 3D structure. (NCT02737930)
Timeframe: baseline to 6 months

Interventionpercent change in microns (Mean)
Fluoxetine-0.02
Placebo-1.49

Median Change in Patient Health Questionnaire-9 Score

This is a self-report inventory used as a screening and diagnostic tool for depression (Appendix F). The 9 items are based on the 9 diagnostic criteria for depression included in the Diagnostic and Statistical Manual of Mental Disorders IV. The scales ranges from 0-27 with higher scores indicating worse outcome. (NCT02737930)
Timeframe: baseline to 6 months

Interventionscore on a scale (Median)
Fluoxetine-1
Placebo0

Median Modified Rankin Scale Score

This is a functional outcome measure widely used in stroke clinical trials, with a score of 0 indicating no disability, 6 indicating death, and scores of 2 or less generally accepted to indicate a favorable functional outcome. (NCT02737930)
Timeframe: 90 days

Interventionscore on a scale (Median)
Fluoxetine1
Placebo2

Number of Participants With >95% Recovery

Recovery is an improvement in the blind visual field. Participants were counted if the percentage of visual field that was blind was reduced by 95%. (NCT02737930)
Timeframe: 6 months

Interventionparticipants (Number)
Fluoxetine3
Placebo1

Percent Change in Mean Visual Function Questionnaire-25 Score

The VFQ-25 consists of a base set of 25 vision targeted questions representing 11 vision-related constructs: global vision rating, difficulty with near vision activities, difficulty with distance vision activities, limitations in social functioning due to vision, role limitations due to vision, dependency on others due to vision, mental health symptoms due to vision, driving difficulties, limitations with peripheral and color vision, and ocular pain. The scores range from 0-100 with higher scores indicating better functioning. (NCT02737930)
Timeframe: baseline to 6 months

Interventionpercent change of units on a scale (Mean)
Fluoxetine-11.2
Placebo-14.9

Percent Change in the Bionocularly Averaged Perimetric Mean Deviation

24-2 Humphrey perimetry was completed for each eye (Zeiss HFAIIi, Swedish Interactive Threshold Algorithm (SITA) Standard, size III white target, fixation enforced, corrected for near vision). The cutoff of a sensitivity of 10 dB to define sighted versus blind test locations was chosen. Perimetric mean deviation is a summary statistic calculated by measuring the deviation from the expected threshold value for stimulation at each point in the visual field and taking an average, with possible values ranging from +2 to -32 dB. (NCT02737930)
Timeframe: baseline to 6 months

Interventionpercent change in dB (Mean)
Fluoxetine64.4
Placebo26.0

Trials

1 trial available for fluoxetine and Altidudinal Hemianopia

ArticleYear
FLUORESCE: A Pilot Randomized Clinical Trial of Fluoxetine for Vision Recovery After Acute Ischemic Stroke.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2023, 06-01, Volume: 43, Issue:2

    Topics: Adult; Double-Blind Method; Fluoxetine; Hemianopsia; Humans; Ischemic Stroke; Pilot Projects; Recove

2023